Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 11

1520P - Preferences on treatment decision making in sarcoma patients. Prevalence and associated factors: Results from the PROSa study

Date

10 Sep 2022

Session

Poster session 11

Topics

Tumour Site

Sarcoma

Presenters

Hanna Salm

Citation

Annals of Oncology (2022) 33 (suppl_7): S681-S700. 10.1016/annonc/annonc1073

Authors

H. Salm1, M. Eichler2, L. Hentschel3, S. Richter2, P. Hohenberger4, B. Kasper5, D. Andreou6, D. Pink7, L. Mütze8, K. Arndt9, M. Bornhaeuser2, J. Schmitt10, M.K. Schuler2

Author affiliations

  • 1 Department Of Internal Medicine C, University Hospital Greifswald, Germany, 17475 - Greifswald/DE
  • 2 Medizinische Klinik I, Universitaetsklinikum Carl Gustav Carus Dresden, 01307 - Dresden/DE
  • 3 National Center For Tumor Diseases (nct/ucc), National Center for Tumor Diseases (NCT/UCC), 01307 - Dresden/DE
  • 4 Div.of Surgical Oncology & Thoracic Surgery, UMM - Universitaetsklinikum Mannheim, 68167 - Mannheim/DE
  • 5 Mannheim Cancer Center (mcc), UMM - Universitaetsklinikum Mannheim, 68167 - Mannheim/DE
  • 6 Tumor Orthopedics, UKM - University Hospital Muenster, 48149 - Muenster/DE
  • 7 Hematology, Oncology And Palliative Care, HELIOS Klinikum Bad Saarow, 15526 - Bad Saarow/DE
  • 8 Internal Medicine, Hospital Emmaus Niesky, 02906 - Niesky/DE
  • 9 Patient Care, German Sarcoma Foundation, 61200 - Woelfersheim/DE
  • 10 Center For Evidence-based Healthcare, University Hospital Carl Gustav Carus, 01307 - Dresden/DE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1520P

Background

The impact of being diagnosed with a life-threatening illness may influence preferences to participate in treatment decisions. The objective of this study was to identify factors that are associated with sarcoma patients wanting to take a more active or passive role.

Methods

Data was obtained as part of a nationwide multicenter trial (PROSa) aiming to investigate the structure and quality of medical care of sarcoma patients in Germany. The study was conducted between 2017 and 2020 in 39 study centers. For the present analysis, cross-sectional data of adult patients with sarcoma of any entity were analyzed. Control preference was measured with the control preference scale (CPS). Preferences were divided in patient-led, shared, or physician-led-decision-making. Associated factors were analyzed exploratively using multivariable nominal logistic regression models. We included socio-economical and medical variables with stepwise backward variable selection.

Results

We included 1059 patients (51.5 % male). 394 patients wanted to make their own treatment decision while 275 patients preferred the physician to make treatment decisions on their behalf. 390 patients wanted to share responsibility. Comparing patients’ preferences to participate, we found the following significant differences: Patient without metastases were more likely to make their own treatment decisions than patients with a metastatic tumor disease who preferred to share responsibility (OR 1.50, 95% CI 1.04; 2.16). With patients between 18 and >40 years as reference category, older patients were less likely to make the decision by themselves: age group: 55-<65 (Odds Ratio (OR) 0.50, 95% confidence interval (95% CI) 0.29; 0.88), age group: 65-<75 (OR 0.39, 95% CI 0.22; 0.69), age group: ≥75 years (OR 0.29, 95% CI 0.15; 0.56). Patients with an education level of high school or higher were more likely to make decisions by themself than those with 8 or 9 years of school education (OR 1.94, 95% CI 1.24; 3.05).

Conclusions

The findings of our study demonstrate that patients with metastatic disease are more likely to seek a joint decision, while those with higher age and lower education level are unlikely to seek an active role in treatment decision making.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

German Cancer Aid (No. 111713).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.